Oromandibular dystonia: a serious side effect of capecitabine

[1] Miwa M(1998)Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274-1281

[2] Ura M(2001)Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2282-2292

[3] Nishida M(2003)Multicenter phase II study of oral capecitabine (Xeloda(”)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 1227-1233

[4] Sawada N(1981)A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 239-245

[5] Ishikawa T(2008)Capecitabine-induced oromandibular dystonia: a case report and literature review Acta Oncol 47 1161-1165

[6] Mori K(1997)Focal dystonia after chemotherapy: a case series J Neurooncol 34 163-167

[7] Hoff PM(2013)Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity Br J Cancer 108 2505-2515

[8] Ansari R(2011)Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer Clin Cancer Res 17 3455-3468

[9] Batist G(2011)PharmGKB summary: fluoropyrimidine pathways Pharmacogenet Genomics 21 237-242

[10] Cox J(2011)Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism Oncologist 16 820-834

[1] Miwa M(1998)Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274-1281

[2] Ura M(2001)Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2282-2292

[3] Nishida M(2003)Multicenter phase II study of oral capecitabine (Xeloda(”)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 1227-1233

[4] Sawada N(1981)A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 239-245

[5] Ishikawa T(2008)Capecitabine-induced oromandibular dystonia: a case report and literature review Acta Oncol 47 1161-1165

[6] Mori K(1997)Focal dystonia after chemotherapy: a case series J Neurooncol 34 163-167

[7] Hoff PM(2013)Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity Br J Cancer 108 2505-2515

[8] Ansari R(2011)Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer Clin Cancer Res 17 3455-3468

[9] Batist G(2011)PharmGKB summary: fluoropyrimidine pathways Pharmacogenet Genomics 21 237-242

[10] Cox J(2011)Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism Oncologist 16 820-834